Kestra Medical Technologies, Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KMTS research report →
Range $30 – $34
Price Chart
About the company
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions.
- CEO
- Brian Webster
- IPO
- 2025
- Employees
- 443
- HQ
- Kirkland, WA, US
Get TickerSpark's AI analysis on KMTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.50B
- P/E
- -10.60
- PEG
- -0.67
- P/S
- 15.79
- P/B
- 7.45
- EV/EBITDA
- -12.95
- Div Yield
- 0.00%
- Gross Margin
- 53.89%
- Op Margin
- -134.48%
- Net Margin
- -140.43%
- ROE
- -64.18%
- ROIC
- -47.98%
Latest fiscal year · YoY change
- Revenue
- $95.13M+59.0%
- Gross Profit
- $48.86M+101.8%
- Op Income
- $-134,739,000
- Net Income
- $-131,612,000-15.6%
- EPS
- $-2.43+52.6%
- OCF Growth
- -5.3%
- FCF Growth
- -15.2%
- 52W High
- $31.99
- 52W Low
- $17.34
- 50D MA
- $27.63
- 200D MA
- $24.13
- Beta
- 0.62
- RSI (14)
- 43
- Avg Volume
- 419.27K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kestra opened fiscal 2027 with 60% revenue growth, 56.5% gross margin, and a raised full-year outlook as management pointed to stronger payer coverage, faster rep ramp, and expanding operating leverage.· September 14, 2026
- Revenue rose 60% year over year to $31 million, with gross margin improving to 56.5% from 45.7%.
- Management raised FY2027 revenue guidance to $141 million, up from $137 million previously, implying 48% growth versus FY2026.
- Gross margin expanded for the 11th straight quarter, and management now sees mid-70s margins in the next few years, above the prior 70% target.
- The company said the second half of FY2027 should be stronger than the first half as newer reps ramp and split territories mature.
- Kestra highlighted payer wins, including a major national payer expanding coverage to non-ischemic patients, and said in-network mix has risen into the low 80s from about 70% at IPO.
First-quarter FY2027 revenue was $31 million, up 60% year over year. Gross margin was 56.5%, compared with 45.7% in the prior-year period, and increased 175 basis points sequentially. GAAP operating expenses were $55.2 million versus $37.7 million a year ago; excluding nonrecurring costs and stock-based compensation, operating expenses were $44.2 million versus $30.3 million. GAAP net loss was $44.1 million, compared with $25.8 million last year, and adjusted EBITDA loss was $24 million versus $19.4 million. Cash used in operating activities was $32.3 million, cash, cash equivalents and investments totaled $245 million, and liquidity was about $320 million including unused term-loan capacity. For FY2027, management raised revenue guidance to $141 million from $137 million, equal to 48% growth versus FY2026.
Brian Webster framed the quarter as evidence that Kestra’s differentiated cardiac recovery platform is gaining traction, citing strong execution, faster new-rep ramp, and share gains in competitive accounts. He emphasized that the market remains underpenetrated and said innovation, payer coverage expansion, and territory optimization should continue to drive growth. His tone was upbeat and confident, repeatedly describing the story as strong and saying the team is “bullish” on the company’s trajectory.
Vaseem Mahboob said revenue growth was driven by market expansion, competitive share gains, a higher in-network mix, and improvements in revenue cycle management. He highlighted gross margin improvement to 56.5% from 45.7%, with higher revenue per fit and lower cost per fit helping drive the result, and said the company now expects mid-70s gross margins over the next few years versus the prior 70% target. On profitability, he noted GAAP operating expenses of $55.2 million, adjusted operating expenses of $44.2 million, a $32.3 million operating cash outflow, and $245 million of cash and investments; he also said the new $200 million term loan strengthens the balance sheet and adds flexibility. He guided FY2027 revenue to $141 million and said burn should decline sequentially through the year.
Analysts focused on why guidance was raised by more than the quarterly beat, and management said the higher outlook reflects stronger KPIs across prescriptions, in-network mix, collections, and field-force ramp, with the second half expected to be faster than the first. Questions also probed the new R&D program and AI initiatives; management said the extra R&D spending is tied to a late-stage project that should be discussed next quarter, while AI is aimed at patient support, revenue-cycle automation, and rep productivity. On payer coverage, management said the new national-payer decision on non-ischemic patients is meaningful but that most large payers already cover that population, making this more of an outlier turning into a positive signal than a broad industry conversion.
Kestra is growing quickly, expanding margins, and still sees a large underpenetrated WCD market, with management citing about 15% U.S. share and 14% market growth over the last 12 months ended July 2026. Better payer coverage, rising in-network mix, and faster-ramping reps could support both revenue growth and margin expansion. Management also sees AI and automation as a path to stronger rep productivity and lower operating-cost intensity over time.
The company is still posting a sizeable GAAP loss and cash burn, with operating cash outflow of $32.3 million in the quarter and adjusted EBITDA loss of $24 million. Management said FY2027 will still include elevated spending, including about $220 million of GAAP operating expenses, while some AI-driven cost benefits are expected more in FY2028 and FY2029 than immediately. The second-half acceleration thesis depends on territory splits, new-hire ramp, and continued payer progress, which introduces execution risk.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 56.6%
- Shares Outstanding
- 59.56M
- Float Shares
- 33.71M
of shares held by institutions
111 13F filers
Buy/sell ratio 0.36. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bain Capital Investors LLC | 25.17M | 0 |
| Fmr LLC | 5.96M | ▲ 434.05K |
| Price T Rowe Associates Inc | 4.97M | ▼ 999.76K |
| Andera Partners | 2.73M | 0 |
| Yu Fan | 2.28M | 0 |
| Blackrock, Inc. | 2.23M | ▲ 365.60K |
| Brown Advisory Inc | 1.91M | ▲ 185.33K |
| Alliancebernstein L.P. | 1.48M | ▲ 157.62K |
| Vanguard Capital Management LLC | 1.33M | ▲ 154.12K |
| Vanguard Group Inc | 1.27M | ▲ 522.18K |
| Eventide Asset Management, LLC | 1.26M | ▼ 188.48K |
| Omega Fund Management, LLC | 1.02M | 0 |
Held by 223 ETFs
Biggest fund positions in KMTS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Webster Brian Daniel | sell | 11,715 |
| Nov 18, 26 | Webster Brian Daniel | sell | 3,285 |
| Nov 3, 26 | Moran Timothy P. | sell | 3,192 |
| Oct 27, 26 | Mahboob Vaseem | other | 34,809 |
| Oct 28, 26 | Mahboob Vaseem | other | 39,903 |
| Oct 27, 26 | Mahboob Vaseem | other | 34,809 |
| Oct 28, 26 | Mahboob Vaseem | other | 39,903 |
| Oct 29, 26 | Mahboob Vaseem | other | 4,788 |
| Oct 29, 26 | Mahboob Vaseem | other | 4,788 |
| Oct 29, 26 | Mahboob Vaseem | sell | 4,788 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KMTS coverage
Recent articles, reports, and earnings notes.
No research on KMTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KMTS report →Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology
globenewswire.com · Nov 16
Kestra Medical Technologies to Participate in Upcoming Investor Conferences
globenewswire.com · Oct 30
Comparing Kestra Medical Technologies (NASDAQ:KMTS) & Bioventus (NASDAQ:BVS)
defenseworld.net · Oct 12
Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Up – Should You Buy?
defenseworld.net · Oct 1
Kestra Medical Technologies Earns Five-Star Rating on Newsweek's List of America's Greatest Mid-Market Companies
globenewswire.com · Oct 1
Kestra Medical: Strong Scaling Story, But Profitability Still On The Horizon
seekingalpha.com · Sep 16
Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Down After Earnings Miss
defenseworld.net · Sep 16
Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com · Sep 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.